Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avecho Biotechnology Ord Shs V.AVE


Primary Symbol: AVEFF

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.


OTCPK:AVEFF - Post by User

Post by kijijion Oct 11, 2018 9:44pm
64 Views
Post# 28785672

DSKE needs some good news cuz its starting to suck

DSKE needs some good news cuz its starting to suck
Analysts expect that Daseke Inc (NASDAQ:DSKE) will post $0.04 earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Daseke’s earnings, with the highest EPS estimate coming in at $0.07 and the lowest estimate coming in at $0.02.  The firm is scheduled to report its next quarterly earnings results on Thursday, November 8th.
 
On average, analysts expect that Daseke will report full-year earnings of $0.14 per share for the current fiscal year, with EPS estimates ranging from $0.09 to $0.19. For the next financial year, analysts expect that the company will post earnings of $0.16 per share, with EPS estimates ranging from $0.03 to $0.40. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Daseke.
<< Previous
Bullboard Posts
Next >>